Immunological therapy of human tumors by gene-modified cellular vaccines.
Parmiani
G
G
Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy.
D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D016207:Cytokines / Q000235:genetics*; D018076:DNA, Complementary / Q000235:genetics; D005260:Female; D006801:Humans; D016233:Immunotherapy, Active; D007376:Interleukin-2 / Q000235:genetics / Q000627:therapeutic use; D008325:Mammary Neoplasms, Experimental / Q000628:therapy; D008545:Melanoma / Q000276:immunology / Q000628:therapy; D051379:Mice; D018448:Models, Immunological; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000276:immunology / Q000378:metabolism / Q000528:radiation effects; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
D019496:Cancer Vaccines; D016207:Cytokines; D018076:DNA, Complementary; D007376:Interleukin-2; D014614:Vaccines, Synthetic